Psoriasis Market Set for Robust Growth Driven by Innovation and Pipeline Advances by 2034 - DelveInsight

DelveInsight's "Psoriasis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Psoriasis, historical and forecasted epidemiology as well as the Psoriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Psoriasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Psoriasis Market Forecast
https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Psoriasis Market Report:
• The Psoriasis market size was valued USD 33,803 million in 2025 and is estimated to grow with a significant CAGR of 1.70% during the study period (2020-2034).
• In July 2026, Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced that the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending orphan medicinal product designation for imsidolimab, the company's investigational high-affinity humanized IgG4 monoclonal antibody for the treatment of generalized pustular psoriasis (GPP). This represents the first orphan drug designation recognition by the EMA for a therapy targeting GPP in the European Union. GPP is a severe, chronic, and potentially life-threatening inflammatory skin disorder that is genetically and clinically distinct from plaque psoriasis. The disease is associated with dysregulation of the interleukin-36 (IL-36) signaling pathway and is characterized by widespread pustular eruptions, systemic inflammation, and serious complications that may increase the risk of mortality.
• In June 2026, Takeda has emerged as a leader in the TYK2 inhibitor space after its investigational therapy zasocitinib outperformed Bristol Myers Squibb's Sotyktu, strengthening the company's position ahead of a potential plaque psoriasis launch next year. The Phase III study directly compared zasocitinib-acquired by Takeda in a $4 billion upfront deal in 2022-with Sotyktu. Previous cross-trial analyses had already indicated a competitive advantage for zasocitinib, with up to 33.4% of patients with moderate-to-severe plaque psoriasis achieving complete skin clearance in Takeda's earlier Phase III trials, compared with up to 14% of patients treated with Sotyktu.
• In June 2026, Japan-based Takeda Pharmaceutical announced that its experimental once-daily psoriasis treatment, zasocitinib, developed with the support of artificial intelligence, demonstrated superior efficacy compared with Bristol Myers Squibb's approved therapy Sotyktu in a late-stage head-to-head clinical trial. The company reported that zasocitinib successfully achieved the primary endpoint in adults with moderate-to-severe plaque psoriasis, delivering greater skin clearance after 16 weeks of treatment than Sotyktu. This positive Phase III outcome highlights the potential of zasocitinib as a promising new treatment option for psoriasis patients.
• In December 2025, Akeda's once-daily oral therapy for plaque psoriasis (PsO) successfully achieved all primary and secondary endpoints in two pivotal Phase III trials, and the company plans to pursue FDA approval in 2026. In the randomized, multicenter, double-blind studies (NCT06088043 and NCT06108544), zasocitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated robust efficacy in adults with moderate-to-severe PsO.
• In December 2025, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced the submission of a Biologics License Application (BLA) to the U.S. FDA for imsidolimab, a novel IgG4 IL-36 receptor antagonist, for the treatment of generalized pustular psoriasis (GPP). Imsidolimab works by inhibiting IL-36 receptor signaling, addressing the deficiency of the endogenous IL-36RA regulator often caused by IL36RN gene mutations in GPP patients. The BLA is supported by positive outcomes from the global Phase 3 GEMINI-1 and GEMINI-2 trials, in which a single intravenous dose of imsidolimab led to rapid skin clearance, achieving clear or nearly clear skin, with efficacy maintained over an approximately two-year maintenance period with monthly dosing. The drug also demonstrated a favorable safety profile with no clinically significant safety concerns.
• In September 2025, The FDA approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking it as the first IL-23 inhibitor to receive this approval in the US.
• In August 2025, Bausch Health Americas Inc. announced a study to assess the safety, systemic exposure, and hypothalamic-pituitary-adrenal (HPA) axis suppression risk of topically applied IDP-118 lotion in pediatric patients with moderate to severe plaque psoriasis.
• In June 2025, Sun Pharmaceutical Industries Limited released top-line findings from its Phase 2 clinical trial assessing the safety and efficacy of SCD-044, an innovative oral sphingosine-1-phosphate (S1P) receptor 1 agonist, in patients with moderate to severe psoriasis. The trial did not achieve its primary goal of demonstrating a 75% improvement in the Psoriasis Area and Severity Index (PASI ≥75) at Week 16. This Phase 2 randomized, double-blind, placebo-controlled study involved 263 participants diagnosed with moderate to severe plaque psoriasis.
• In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, SFA-002, will be presented at the American Academy of Dermatology Annual Meeting in Orlando, Florida.
• In May 2025, Johnson & Johnson (J&J) released updated findings from its Phase III ICONIC-TOTAL trial investigating icotrokinra, an oral peptide, for the treatment of plaque psoriasis (PsO). The randomized study included both adult and adolescent patients aged 12 years and older, with a body surface area involvement as low as 1% and moderate or greater psoriasis affecting key skin regions.
• In February 2025, Bristol Myers Squibb (BMS), a US-based pharmaceutical company, announced results from the POETYK PSO long-term extension (LTE) trial evaluating Sotyktu (deucravacitinib) for plaque psoriasis. The LTE trial included the 52-week POETYK PSO-1 and POETYK PSO-2 studies, involving 1,221 participants who received a 6mg daily dose of open-label Sotyktu.
• In February 2025, Vyne Therapeutics initiated a randomized Phase Ib clinical trial by dosing the first participant with VYN202, an oral therapy for moderate-to-severe plaque psoriasis. This double-blind, placebo-controlled study includes three dosing groups to evaluate the treatment's safety, pharmacokinetics, and tolerability. Participants will receive either 0.25mg, 0.5mg, or 1mg doses of VYN202, or a placebo, administered once daily over a 12-week period.
• In December 2024, Bristol Myers Squibb (NYSE: BMY) announced findings from the POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055) Phase 3 trials assessing the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both studies achieved their primary endpoint, demonstrating a significantly higher percentage of Sotyktu-treated patients attaining an ACR20 response-indicating at least a 20% improvement in disease signs and symptoms-after 16 weeks of treatment compared to placebo.
• In October 2024, InnoCare Pharma reported that its Phase II clinical trial of the Tyrosine Kinase 2 (TYK2) inhibitor ICP-488 for psoriasis treatment achieved the primary endpoint. The multicenter, randomized, double-blind, placebo-controlled study aimed to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ICP-488 in adult Chinese patients with moderate-to-severe plaque psoriasis.
• In August 2024, Amgen (NASDAQ:AMGN) announced today that Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for treating moderate to severe plaque psoriasis in children and adolescents aged 6 and older, weighing at least 20 kg (44 lb), and who are suitable candidates for phototherapy or systemic therapy. Currently, there are no other FDA-approved oral treatments for moderate to severe plaque psoriasis in this age group.
• In the 7MM, the United States accounted for the largest share of the psoriasis market, valued at approximately USD 26,740 million in 2024, with growth expected by 2034.
• In 2024, the total diagnosed prevalent cases of psoriasis across the 7MM were estimated at around 15,887,640.
• Among the location-specific types, scalp psoriasis recorded the highest number of cases in the US, reaching approximately 4,811,170 in 2024.
• Within the EU4 and the UK, Germany reported the highest number of plaque psoriasis cases at approximately 2,099,495 in 2024, while Spain had the lowest, with around 1,042,368 cases in the same year.
• In 2024, psoriasis was primarily seen in adults, representing about 97% of all reported cases across the 7MM.
• IL-23 inhibitors, including TREMFYA, SKYRIZI, and ILUMYA, are recognized for their good tolerability and established long-term safety. In contrast, IL-17 inhibitors like COSENTYX, TALTZ, and SILIQ have shown quicker psoriasis clearance compared to IL-23 inhibitors.
• In 2024, CMS revealed the newly negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), including STELARA (ustekinumab) and ENBREL (etanercept), which are anticipated to encounter biosimilar competition in 2025 and 2029, respectively.
• In 2024, CMS announced the updated negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), including STELARA (ustekinumab) and ENBREL (etanercept), which are expected to face biosimilar competition in 2025 and 2029, respectively.
• Key Psoriasis Companies: UCB Pharma, Novartis, Sun Pharmaceutical/ Almirall, Bausch Health, Boehringer Ingelheim, LEO Pharma, AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma, E-nitiate Biopharmaceuticals, SFA Therapeutics, Rubedo Life Sciences, Inc, and others
• Key Psoriasis Therapies: BIMZELX, COSENTYX, ILUMYA/ILUMETR, BRYHALI, SPEVIGO, ENSTILAR, Imsidolimab, TAK-279, Sonelokimab, Piclidenoson, QY101, SFA 002, RLS-1496, and others
• The Psoriasis epidemiology based on gender analyzed that the prevalence of moderate cases is the highest, followed by severe and mild cases
• The Psoriasis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psoriasis pipeline products will significantly revolutionize the Psoriasis market dynamics.

Psoriasis Overview
Plaque psoriasis is a chronic autoimmune skin condition characterized by red, raised, and scaly patches called plaques, typically appearing on the elbows, knees, scalp, and lower back. It occurs when the immune system accelerates skin cell production, causing cells to accumulate on the surface. Symptoms may include itching, discomfort, and cracking, and while it is not contagious, it can impact quality of life. Treatment often involves topical therapies, phototherapy, or systemic medications to reduce inflammation and slow skin cell turnover.

Get a Free sample for the Psoriasis Market Report:
https://www.delveinsight.com/report-store/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Psoriasis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Psoriasis Epidemiology Segmentation:
The Psoriasis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Psoriasis
• Prevalent Cases of Psoriasis by severity
• Gender-specific Prevalence of Psoriasis
• Diagnosed Cases of Episodic and Chronic Psoriasis

Download the report to understand which factors are driving Psoriasis epidemiology trends @ Psoriasis Epidemiology Forecast
https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Psoriasis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psoriasis market or expected to get launched during the study period. The analysis covers Psoriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Psoriasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Psoriasis Therapies and Key Companies
• BIMZELX: UCB Pharma
• COSENTYX: Novartis
• ILUMYA/ILUMETRI: Sun Pharmaceutical/ Almirall
• BRYHALI: Bausch Health
• SPEVIGO: Boehringer Ingelheim
• ENSTILAR: LEO Pharma
• Imsidolimab: AnaptysBio
• TAK-279: Nimbus Lakshmi/Takeda
• Sonelokimab: MoonLake Immunotherapeutics
• Piclidenoson: Can-Fite Biopharma
• Sonelokimab: MoonLake Immunotherapeutics
• QY101: E-nitiate Biopharmaceuticals
• SFA 002: SFA Therapeutics
• RLS-1496: Rubedo Life Sciences, Inc

Discover more about therapies set to grab major Psoriasis market share @ Psoriasis Treatment Market
https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Psoriasis Market Drivers
• Rising disease prevalence and diagnosis rates are expanding the patient pool, increasing demand for effective long-term treatment options.
• Growing adoption of biologics and targeted therapies such as IL-17, IL-23, and TNF inhibitors is driving market growth due to their superior efficacy and safety profiles.
• Advancements in precision medicine and biomarker research are enabling personalized treatment approaches, improving patient outcomes and therapy uptake.
• Increasing awareness campaigns and patient advocacy initiatives are promoting early diagnosis and treatment, particularly in emerging markets.
• Strong pipeline activity and continuous regulatory approvals are introducing novel therapies with improved convenience, efficacy, and durability.

Psoriasis Market Barriers
• High cost of biologic therapies remains a significant challenge, limiting access for many patients, especially in low- and middle-income countries.
• Patent expirations and biosimilar competition are exerting pricing pressure on established branded products and affecting revenue growth.
• Stringent regulatory requirements and lengthy clinical development timelines can delay the launch of innovative therapies.
• Safety concerns associated with long-term immunosuppressive treatments, including infection risks, may impact treatment adoption and persistence.
• Limited treatment access and reimbursement restrictions in certain regions continue to hinder market penetration.

Scope of the Psoriasis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Psoriasis Companies: UCB Pharma, Novartis, Sun Pharmaceutical/ Almirall, Bausch Health, Boehringer Ingelheim, LEO Pharma, AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma, E-nitiate Biopharmaceuticals, SFA Therapeutics, Rubedo Life Sciences, Inc, and others
• Key Psoriasis Therapies: BIMZELX, COSENTYX, ILUMYA/ILUMETR, BRYHALI, SPEVIGO, ENSTILAR, Imsidolimab, TAK-279, Sonelokimab, Piclidenoson, QY101, SFA 002, RLS-1496, and others
• Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies
• Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Psoriasis Unmet Needs, KOL's views, Analyst's views, Psoriasis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.